The Efficacy of a Standardized Acupuncture Regimen and Amitriptyline Compared With Placebo as a Treatment for Pain Caused by Peripheral Neuropathy in HIV-Infected Patients

Overview

To evaluate the separate and combined efficacy of a standardized acupuncture regimen and amitriptyline on the relief of pain due to peripheral neuropathy and on the quality of life of HIV-infected patients. Both amitriptyline, an antidepressant, and acupuncture, a Chinese medical approach that uses needles to relieve pain, have been used successfully to reduce pain in some people. It is not known how effectively these approaches relieve or reduce pain in patients with peripheral neuropathy secondary to HIV infection.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Care Provider)

Detailed Description

Both amitriptyline, an antidepressant, and acupuncture, a Chinese medical approach that uses needles to relieve pain, have been used successfully to reduce pain in some people. It is not known how effectively these approaches relieve or reduce pain in patients with peripheral neuropathy secondary to HIV infection. Patients are randomized to receive either standardized point acupuncture or alternate point acupuncture treatment twice weekly for the first 6 weeks, then once weekly for the next 8 weeks, plus either oral amitriptyline or placebo daily for the entire 14 weeks. Acupuncture points are located on the lower leg. Patients are evaluated at weeks 6 and 14 and are asked to keep a daily pain diary.

Interventions

  • Drug: Amitriptyline hydrochloride
    • 75 mg oral tablet taken daily
  • Drug: Amitriptyline hydrochloride placebo
    • Oral placebo tablet taken daily
  • Procedure: Point acupuncture
    • Standardized or alternate acupuncture procedure

Arms, Groups and Cohorts

  • Experimental: 1
    • Participants will receive standardized or alternate point acupuncture treatment twice weekly for the first 6 weeks, then once weekly for the next 8 weeks, plus either oral amitriptyline or placebo daily for the entire 14 weeks.

Clinical Trial Outcome Measures

Primary Measures

  • Change in intensity of pain as measured by the daily pain diary and the global pain relief rating
    • Time Frame: At Weeks 6 and 14
  • Change in quality life
    • Time Frame: Throughout study
  • Change in neurological status
    • Time Frame: Throughout study
  • Permanent discontinuation of study treatment due to treatment failure
    • Time Frame: Throughout study

Participating in This Clinical Trial

Inclusion Criteria Concurrent Medication: Allowed:

  • Antiretroviral therapy. – Nonsystemic treatment of Kaposi's sarcoma. – Maintenance with an existing regimen of analgesic medication or herbal treatment. Concurrent Treatment: Required: – Acupuncture. Patients must have: – HIV infection. – Lower extremity peripheral neuropathy secondary to HIV infection. – Pain for at least 2 weeks prior to study entry. – Life expectancy of at least 6 months. NOTE: – Co-enrollment in other experimental protocols is permitted as long as dual participation is allowed in those protocols. Prior Medication: Allowed: – Antiretroviral therapy. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: – Known allergy to amitriptyline (not applicable for patients at sites using an acupuncture only study design). – EKG indicating malignant arrhythmia or cardiac conduction disturbances (not applicable for patients at sites using an acupuncture only study design). – Prison incarceration. Concurrent Medication: Excluded: – Active treatment for an acute opportunistic infection or malignancy (nonsystemic treatment of Kaposi's sarcoma is permitted). – Other tricyclic antidepressants. – MAO inhibitors. Patients with the following prior conditions are excluded (not applicable for patients at sites using an acupuncture only study design): – History of cardiac disease. – History of seizure disorder. Prior Medication: Excluded within 2 weeks prior to study entry: – MAO inhibitors. – Tricyclic antidepressants.

Gender Eligibility: All

Minimum Age: 13 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • National Institute of Allergy and Infectious Diseases (NIAID)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Shlay J, Study Chair,
    • Flaws B, Study Chair,

References

Chavez C. Prickly business. The finer points of acupuncture. Posit Aware. 1995 Jan-Feb:14-5.

Shlay JC, Chaloner K, Max MB, Flaws B, Reichelderfer P, Wentworth D, Hillman S, Brizz B, Cohn DL. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA. 1998 Nov 11;280(18):1590-5. doi: 10.1001/jama.280.18.1590.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.